Search results
Results from the WOW.Com Content Network
The United States' Orphan Drug Act includes both rare diseases and any non-rare diseases "for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will [be] recovered from sales in the United States of such drug" as orphan diseases. [13]
A rare disease is technically defined (in the European Union) as a disease that is found in fewer than 5 people per every 10,000 people. ...
According to the US Food and Drug Administration (FDA), an orphan drug is defined as one "intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects less than 200,000 persons in the US" (which equates to approximately 6 cases per 10,000 population) "or meets cost recovery provisions of the act".
The oral drug, branded as Miplyffa, has now been approved for the treatment of Neimann-Pick disease type C - a rare genet US FDA approves Zevra's treatment for rare genetic disease Skip to main ...
The Orphan Drug Act of 1983 is a law passed in the United States to facilitate development of orphan drugs—drugs for rare diseases such as Huntington's disease, myoclonus, ALS, Tourette syndrome or muscular dystrophy which affect small numbers of individuals residing in the United States.
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic ... that people take to manage chronic diseases. ... drug has a similar list price of $3.5 million in ...
On Sept. 20, the FDA approved Zevra's drug, Miplyffa, for the treatment of NPC - the first treatment to get a nod for the condition US FDA approves IntraBio's drug for rare genetic disease Skip to ...
In some parts of the world, an ultra-orphan disease is a rare disease whose rarity means there is a lack of a market large enough to have support and resources for discovering treatments for it. [1] [2] [3] Distinct countries define and provide special economic incentives for companies developing drugs that treat ultra-rare diseases.